Kelsey E. Sivick

4.2k total citations · 2 hit papers
16 papers, 2.8k citations indexed

About

Kelsey E. Sivick is a scholar working on Immunology, Molecular Biology and Infectious Diseases. According to data from OpenAlex, Kelsey E. Sivick has authored 16 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Immunology, 7 papers in Molecular Biology and 5 papers in Infectious Diseases. Recurrent topics in Kelsey E. Sivick's work include interferon and immune responses (5 papers), Immune Response and Inflammation (5 papers) and Escherichia coli research studies (4 papers). Kelsey E. Sivick is often cited by papers focused on interferon and immune responses (5 papers), Immune Response and Inflammation (5 papers) and Escherichia coli research studies (4 papers). Kelsey E. Sivick collaborates with scholars based in United States, France and Russia. Kelsey E. Sivick's co-authors include Harry L. T. Mobley, Thomas W. Dubensky, Sarah M. McWhirter, Laura Hix Glickman, Justin J. Leong, David B. Kanne, Edward E. Lemmens, Ken Metchette, George E. Katibah and Leticia Corrales and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and The Journal of Cell Biology.

In The Last Decade

Kelsey E. Sivick

15 papers receiving 2.8k citations

Hit Papers

Direct Activation of STING in the Tumor Microenvironment ... 2015 2026 2018 2022 2015 2015 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
    2015 1.1k citations Leticia Corrales, Laura Hix Glickman et al. Cell Reports profile →
  2. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
    2015 581 citations Juan Fu, David B. Kanne et al. Science Translational Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kelsey E. Sivick United States 13 1.9k 984 647 640 453 16 2.8k
Nicole Tegtmeyer Germany 40 2.1k 1.1× 1.1k 1.1× 577 0.9× 314 0.5× 294 0.6× 91 4.5k
Sky W. Brubaker United States 13 1.6k 0.9× 1.4k 1.4× 378 0.6× 190 0.3× 311 0.7× 14 2.6k
Teresa Frisan Sweden 31 905 0.5× 1.2k 1.2× 435 0.7× 814 1.3× 463 1.0× 66 3.0k
Kevin W. Bruhn United States 24 1.5k 0.8× 938 1.0× 201 0.3× 605 0.9× 365 0.8× 36 2.7k
Anna Sokolovska United States 18 1.2k 0.6× 1.3k 1.4× 352 0.5× 258 0.4× 378 0.8× 24 2.8k
Jérôme Le Nours Australia 27 2.4k 1.3× 688 0.7× 273 0.4× 560 0.9× 450 1.0× 48 3.4k
J P Tite United Kingdom 31 2.2k 1.2× 741 0.8× 354 0.5× 347 0.5× 459 1.0× 75 3.4k
Margaret Goodall United Kingdom 31 1.7k 0.9× 1.3k 1.3× 413 0.6× 216 0.3× 334 0.7× 76 3.6k
Ulf Yrlid Sweden 30 2.0k 1.1× 540 0.5× 377 0.6× 272 0.4× 202 0.4× 63 2.8k
Giovanni Suárez United States 31 1.2k 0.6× 741 0.8× 226 0.3× 239 0.4× 431 1.0× 51 2.8k

Countries citing papers authored by Kelsey E. Sivick

Since Specialization
Citations

This map shows the geographic impact of Kelsey E. Sivick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kelsey E. Sivick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kelsey E. Sivick more than expected).

Fields of papers citing papers by Kelsey E. Sivick

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kelsey E. Sivick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kelsey E. Sivick. The network helps show where Kelsey E. Sivick may publish in the future.

Co-authorship network of co-authors of Kelsey E. Sivick

This figure shows the co-authorship network connecting the top 25 collaborators of Kelsey E. Sivick. A scholar is included among the top collaborators of Kelsey E. Sivick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kelsey E. Sivick. Kelsey E. Sivick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Zhu, Wandi S., Jaskirat Singh, Rebecca D. Ray, et al.. (2025). Casdatifan (AB521) is a novel and potent allosteric small molecule inhibitor of protumourigenic HIF‐2α dependent transcription. British Journal of Pharmacology. 182(17). 4147–4167.
2.
Groot, Amber E. de, Soonweng Cho, Rebecca D. Ray, et al.. (2024). Fc-Silent Anti-TIGIT Antibodies Potentiate Antitumor Immunity without Depleting Regulatory T Cells. Cancer Research. 84(12). 1978–1995. 8 indexed citations
3.
Espinosa, Diego A., P. Robert Beatty, Gabrielle L. Reiner, et al.. (2019). Cyclic Dinucleotide–Adjuvanted Dengue Virus Nonstructural Protein 1 Induces Protective Antibody and T Cell Responses. The Journal of Immunology. 202(4). 1153–1162. 24 indexed citations
4.
Francica, Brian J., Ali Ghasemzadeh, Anthony L. Desbien, et al.. (2018). TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors. Cancer Immunology Research. 6(4). 422–433. 67 indexed citations
5.
Dis, Erik Van, Kimberly M. Sogi, Chris S. Rae, et al.. (2018). STING-Activating Adjuvants Elicit a Th17 Immune Response and Protect against Mycobacterium tuberculosis Infection. Cell Reports. 23(5). 1435–1447. 91 indexed citations
6.
Corrales, Leticia, Laura Hix Glickman, Sarah M. McWhirter, et al.. (2015). Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Reports. 11(7). 1018–1030. 1146 indexed citations breakdown →
7.
Fu, Juan, David B. Kanne, Meredith L. Leong, et al.. (2015). STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Science Translational Medicine. 7(283). 283ra52–283ra52. 581 indexed citations breakdown →
8.
Sivick, Kelsey E., et al.. (2014). Toll-like Receptor-Deficient Mice Reveal How Innate Immune Signaling Influences Salmonella Virulence Strategies. Cell Host & Microbe. 15(2). 203–213. 31 indexed citations
9.
Corrales, Leticia, Laura Hix Glickman, Sarah M. McWhirter, et al.. (2014). Direct activation of STING in the tumor microenvironment with synthetic cyclic dinucleotide derivatives leads to potent and systemic tumor-specific immunity. Journal for ImmunoTherapy of Cancer. 2(S3). 2 indexed citations
10.
Arpaia, Nicholas, Jernej Godec, Laura Lau, et al.. (2011). TLR Signaling Is Required for Salmonella typhimurium Virulence. Cell. 144(5). 675–688. 196 indexed citations
11.
Sivick, Kelsey E., Matthew Schaller, Sara N. Smith, & Harry L. T. Mobley. (2010). The Innate Immune Response to Uropathogenic Escherichia coli Involves IL-17A in a Murine Model of Urinary Tract Infection. The Journal of Immunology. 184(4). 2065–2075. 108 indexed citations
12.
Alteri, Christopher J., Erin C. Hagan, Kelsey E. Sivick, Sara N. Smith, & Harry L. T. Mobley. (2009). Mucosal Immunization with Iron Receptor Antigens Protects against Urinary Tract Infection. PLoS Pathogens. 5(9). e1000586–e1000586. 149 indexed citations
13.
Sivick, Kelsey E. & Harry L. T. Mobley. (2009). Waging War against UropathogenicEscherichia coli: Winning Back the Urinary Tract. Infection and Immunity. 78(2). 568–585. 172 indexed citations
14.
Crimmins, Gregory, Anat A. Herskovits, Kai Rehder, et al.. (2008). Listeria monocytogenes multidrug resistance transporters activate a cytosolic surveillance pathway of innate immunity. Proceedings of the National Academy of Sciences. 105(29). 10191–10196. 86 indexed citations
15.
Sivick, Kelsey E., et al.. (2006). Protease Activity, Secretion, Cell Entry, Cytotoxicity, and Cellular Targets of Secreted Autotransporter Toxin of Uropathogenic Escherichia coli. Infection and Immunity. 74(11). 6124–6134. 46 indexed citations
16.
Sivick, Kelsey E., et al.. (2006). Protein disulfide isomerase–like proteins play opposing roles during retrotranslocation. The Journal of Cell Biology. 173(6). 853–859. 97 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicole Tegtmeyer Breakdown of academic impact, for papers by Sky W. Brubaker Breakdown of academic impact, for papers by Teresa Frisan Breakdown of academic impact, for papers by Kevin W. Bruhn Breakdown of academic impact, for papers by Anna Sokolovska Breakdown of academic impact, for papers by Jérôme Le Nours Breakdown of academic impact, for papers by J P Tite Breakdown of academic impact, for papers by Margaret Goodall Breakdown of academic impact, for papers by Ulf Yrlid Breakdown of academic impact, for papers by Giovanni Suárez
Rankless by CCL
2026